How Fast Does Tigecycline Clear Infections?
Tigecycline, a glycylcycline antibiotic, kills bacteria by inhibiting protein synthesis, targeting complicated skin infections, intra-abdominal infections, and community-acquired pneumonia caused by resistant pathogens like MRSA or Acinetobacter.[1] Clinical clearance varies by infection site, severity, pathogen, and patient factors, but trials show symptom improvement in 48-72 hours for many cases, with full microbiological eradication in 70-90% by treatment end.[2]
Typical Treatment Duration and Response Timeline
Standard dosing is 100 mg IV loading dose, then 50 mg IV every 12 hours for 5-14 days.[1]
- Skin and soft tissue infections: Clinical response (reduced fever, lesion improvement) by day 2-3 in ~80% of patients; 85-93% cure rate at test-of-cure (12-14 days post-therapy).[2][3]
- Intra-abdominal infections: Fever resolution and source control often within 48 hours; overall success 80-90% after 5-7 days.[3]
- Pneumonia: Improvement in respiratory symptoms by day 3-5; success rates 70-85%, lower in ventilator-associated cases due to higher MICs.[2]
Eradication depends on MIC ≤2 mcg/mL; response slows with higher resistance.[4]
Factors Affecting Speed of Elimination
Patient comorbidities (e.g., obesity, renal impairment) delay clearance since tigecycline relies on biliary/fecal elimination, not kidneys.[1] Biofilm infections or polymicrobial cases extend time to resolution. In trials, 20-30% of failures link to inadequate source control or resistance emergence.[3]
Common Side Effects During Treatment
Nausea (20-30%) and vomiting (15-20%) peak early (days 1-3), potentially interrupting therapy and slowing recovery. Monitor for superinfections like C. difficile, which can prolong hospitalization.[1][2]
When Does It Fail to Clear Quickly?
Failure rates rise to 20-40% in severe sepsis, carbapenem-resistant infections, or if MIC >4 mcg/mL. Switch to alternatives like colistin if no response by day 3-5.[4] No pediatric data shows faster clearance.
[1]: Tigecycline Prescribing Information (FDA)
[2]: NEJM Tigecycline Trials (2005)
[3]: Clinical Infectious Diseases Review (2010)
[4]: Antimicrobial Agents and Chemotherapy (2013)